Hims Daily (Apr 14, 2025)

RFK calls for “European-level” GLP-1 pricing

Apr 14, 2025

Today: +$1.06 (+3.89%)
Past month: -$4.85 (-14.63%)
Past year: +$14.33 (+102.65%)

🚨 Q2 is underway — and Hims is no longer offering commercial-dose semaglutide. We’ll break down the early impact to Q2 sales later this week, exclusively for Hims House subscribers. Subscribe now for access:

What’s Happening

Shares gained nearly 4% today after hitting a high of $29 and dipping to $27.20 mid-morning
RFK’s call for “European-level” GLP-1 pricing (from $1,300 down to <$100) could spark a HUGE demand surge in the United States. Opinions are mixed on how this would impact HIMS:
- One possibility is that this would undermine one of HIMS’ biggest selling points—affordability
- On the other hand, falling prices could spark a surge in demand and reignite supply shortages. In that scenario, HIMS would benefit because it would be allowed to compound semaglutide to fill the supply gap
Sherwood News (Robinhood's media arm) published a story about HIMS on Friday (LINK HERE), picking up the thread from our interview with Andrew Dudum that the company wants to be the “Netflix of the healthcare industry”
Pharma tariff concerns are now center stage, as President Trump reiterated plans to impose tariffs on imported drugs. This triggered lively debates among investors about potential margin impacts on large foreign pharma companies—and whether HIMS’ U.S.-oriented model actually stands to benefit.
- There continues to be tremendous uncertainty about where HIMS sources its active ingredients, though many investors believe they come from India or China. Likewise, it remains unclear how potential pharma tariffs would affect HIMS. Or how HIMS will be impacted relative to larger companies like Novo Nordisk.
Pfizer’s decision to discontinue its weight-loss pill drew attention, with many interpreting it as bullish for HIMS’ weight loss offerings, given reduced competitive pressure.
🚨 If you're an expert on the GLP-1 supply chain and would be up for joining the Hims House podcast in the next few weeks, we'd love to chat! Just reply to this email